Older

Psoriatic arthritis: recent progress in pathophysiology and drug development.

Veale DJ.

Arthritis Res Ther. 2013;15(6):224

Mitochondrial mutagenesis correlates with the local inflammatory environment in arthritis.

Harty LC, Biniecka M, O’Sullivan J, Fox E, Mulhall K, Veale DJ, Fearon U.

Ann Rheum Dis. 2012 Apr;71(4):582-8.

Macrophages in synovial inflammation.

Kennedy A, Fearon U, Veale DJ, Godson C.

Front Immunol. 2011 Oct 10;2:52.

Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis.

Biniecka M, Fox E, Gao W, Ng CT, Veale DJ, Fearon U, O’Sullivan J.

Arthritis Rheum. 2011 Aug;63(8):2172-82.

Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis.

Biniecka M, Kennedy A, Ng CT, Chang TC, Balogh E, Fox E, Veale DJ, Fearon U, O’Sullivan JN.

Arthritis Res Ther. 2011 Jul 25;13(4):R121

Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia.

Kennedy A, Ng CT, Chang TC, Biniecka M, O’Sullivan JN, Heffernan E, Fearon U, Veale DJ.

Arthritis Rheum. 2011 Apr;63(4):923-32

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group.

N Engl J Med. 2010 Jul 15;363(3):221-32